The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of GTx-024, a selective androgen receptor modulator (SARM), on physical function in patients with non-small cell lung cancer (NSCLC) with cancer cachexia.
M. S. Steiner
Employment or Leadership Position - GTx
Stock Ownership - GTx
A. Dobs
Research Funding - GTx
M. L. Hancock
Employment or Leadership Position - GTx
Stock Ownership - GTx
M. A. Johnston
Employment or Leadership Position - GTx
Stock Ownership - GTx
G. Barnette
Employment or Leadership Position - GTx
Stock Ownership - GTx
S. Dodson
Employment or Leadership Position - GTx
Stock Ownership - GTx